Eli Lilly Rises, Shake Shack Declines, Abercrombie & Fitch Sinks

Stock Movers

On this episode of Stock Movers:

- Eli Lilly (LLY) said Monday it expects its highly anticipated weight-loss pill to receive US regulatory approval as early as the second quarter of 2026, slightly later than it signaled earlier. Drugmakers believe weight-loss pills could expand the market for popular GLP-1 medicines, which up until earlier this year were only sold as injections. In December, Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from Lilly.

- Shake Shack (SHAK) shares slipped after the burger chain reported preliminary fourth-quarter sales below Wall Street estimates. Preliminary revenue was $400.5 million, below the $409 million average estimate of analysts surveyed by Bloomberg, with Shake Shack blaming inclement weather for keeping diners away. Shake Shack expects sales to expand by low-single digits in 2026, compared with analyst expectations for 2.4% growth, and plans to open 95 to 105 company-operated and licensed locations this year.

- Abercrombie & Fitch (ANF) shares sank after holiday sales disappointed investors, helping spark a selloff in retail stocks. The company now expects fourth-quarter sales growth of around 5%, the mid-point of its prior range, and didn’t raise its outlook. Shares of Abercrombie plummeted 18% on Monday, while American Eagle and Urban Outfitters also sank after their holiday results underwhelmed Wall Street.

See omnystudio.com/listener for privacy information.

More description

On this episode of Stock Movers:

- Eli Lilly (LLY) said Monday it expects its highly anticipated weight-loss pill to receive US regulatory approval as early as the second quarter of 2026, slightly later than it signaled earlier. Drugmakers believe weight-loss pills could expand the market for popular GLP-1 medicines, which up until earlier this year were only sold as injections. In December, Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from Lilly.

- Shake Shack (SHAK) shares slipped after the burger chain reported preliminary fourth-quarter sales below Wall Street estimates. Preliminary revenue was $400.5 million, below the $409 million average estimate of analysts surveyed by Bloomberg, with Shake Shack blaming inclement weather for keeping diners away. Shake Shack expects sales to expand by low-single digits in 2026, compared with analyst expectations for 2.4% growth, and plans to open 95 to 105 company-operated and licensed locations this year.

- Abercrombie & Fitch (ANF) shares sank after holiday sales disappointed investors, helping spark a selloff in retail stocks. The company now expects fourth-quarter sales growth of around 5%, the mid-point of its prior range, and didn’t raise its outlook. Shares of Abercrombie plummeted 18% on Monday, while American Eagle and Urban Outfitters also sank after their holiday results underwhelmed Wall Street.

See omnystudio.com/listener for privacy information.

2026-01-12 5 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.